Pfizer Still Looking To Buy A Tax Advantage – And Before Congress Flips
This article was originally published in Scrip
Pfizer Inc. CEO Ian Read said the company is evaluating tax inversion M&A opportunities but noted the big pharma would need to complete such a deal by the end of 2016, after which a new Congress would be in place – presenting further regulatory risks.
You may also be interested in...
The company said during its R&D day that it has culled its pipeline to 103 clinical stage assets, choosing to focus on drugs that could be big blockbusters.
New York has its eye on becoming a premier biotech hub and is investing heavily in life sciences. Experts weighed in on the positives and drawbacks of the city for biotechs at a new innovation campus called Cure.
Bristol Myers and 2seventy bio are hoping Abecma will be the first CAR-T therapy for earlier lines of multiple myeloma, but an advisory committee meeting will hold up the sBLA.